{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:53:50Z","timestamp":1792522430371,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clnu.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:55:51Z","timestamp":1761378951000},"page":"42-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"55","author":[{"given":"Wenjie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhuo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaokai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0126-4978","authenticated-orcid":false,"given":"Qiong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2025.10.006_bib1","series-title":"World population ageing","year":"2020"},{"key":"10.1016\/j.clnu.2025.10.006_bib2","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc23-S013","article-title":"13. Older adults: standards of care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2025.10.006_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clnu.2025.10.006_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108078","article-title":"Diabetes and global ageing among 65-99-year-old adults: findings from the international diabetes Federation diabetes atlas, 9(th) edition","volume":"162","author":"Sinclair","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clnu.2025.10.006_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(14)70176-7","article-title":"Diabetes in older people: new insights and remaining challenges","volume":"3","author":"Sinclair","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnu.2025.10.006_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081958","article-title":"The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms","volume":"10","author":"Massimino","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.clnu.2025.10.006_bib7","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.2147\/DDDT.S381546","article-title":"An effective glucagon-like Peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in Obese mice by modulating skeletal muscle metabolism","volume":"16","author":"Ren","year":"2022","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.clnu.2025.10.006_bib8","article-title":"Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2025.10.006_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clnu.2025.10.006_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1573399810666140918121022","article-title":"Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II","volume":"10","author":"Cetrone","year":"2014","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.clnu.2025.10.006_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166770","article-title":"Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice","volume":"1869","author":"Iwai","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.clnu.2025.10.006_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40266-023-01042-4","article-title":"Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia - a narrative review","volume":"40","author":"Witham","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clnu.2025.10.006_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metabol"},{"key":"10.1016\/j.clnu.2025.10.006_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.20517\/mtod.2022.26","article-title":"Pharmacological management of type 2 diabetes: clinical considerations and future perspectives","volume":"3","author":"Jason","year":"2023","journal-title":"Metabol Target Organ Dam"},{"key":"10.1016\/j.clnu.2025.10.006_bib15","first-page":"18","article-title":"Diabetes mellitus and heart disease","volume":"4","author":"Preethi","year":"2024","journal-title":"Metabol Target Organ Dam"},{"key":"10.1016\/j.clnu.2025.10.006_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s11033-024-09793-y","article-title":"From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists","volume":"51","author":"Dave","year":"2024","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.clnu.2025.10.006_bib17","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2025.10.006_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.20517\/mtod.2023.27","article-title":"Metabolic bariatric surgery in face of new anti-obesity medications-10 + 1 challenges","volume":"3","author":"Athanasios","year":"2023","journal-title":"Metabol Target Organ Dam"},{"key":"10.1016\/j.clnu.2025.10.006_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.14740\/jocmr3647","article-title":"Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in Obese patients with type 2 diabetes: a prospective case series","volume":"11","author":"Ishii","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.clnu.2025.10.006_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13370","article-title":"The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis","volume":"23","author":"Nuijten","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.clnu.2025.10.006_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1249\/MSS.0000000000001448","article-title":"Associations of muscle mass and strength with all-cause mortality among US older adults","volume":"50","author":"Li","year":"2018","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.clnu.2025.10.006_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.clnu.2025.10.006_bib23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cardfail.2024.01.005","article-title":"Malnutrition and sarcopenia as reasons for caution with GLP-1 receptor agonist use in HFpEF","volume":"30","author":"Driggin","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.clnu.2025.10.006_bib24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jdiacomp.2018.05.018","article-title":"The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis","volume":"32","author":"Yajima","year":"2018","journal-title":"J Diabetes Complicat"},{"issue":"Suppl 4","key":"10.1016\/j.clnu.2025.10.006_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2025.10.006_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.14740\/jocmr4987","article-title":"Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes","volume":"15","author":"Uchiyama","year":"2023","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.clnu.2025.10.006_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2025.10.006_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158214","article-title":"Impact of selected glucagon-like Peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle Metabolism-A narrative review","volume":"25","author":"Szekeres","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnu.2025.10.006_bib29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong","year":"2019","journal-title":"J Cach Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2025.10.006_bib30","doi-asserted-by":"crossref","first-page":"21962","DOI":"10.18632\/aging.203546","article-title":"Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice","volume":"13","author":"Khin","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.clnu.2025.10.006_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clnu.2025.10.006_bib32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes"},{"key":"10.1016\/j.clnu.2025.10.006_bib33","first-page":"308","article-title":"Comparison of the impact of SGLT2-Inhibitors and exenatide on body fat composition","volume":"33","author":"Agcakaya","year":"2023","journal-title":"J Coll Phys Surg Pak : JCPSP"},{"key":"10.1016\/j.clnu.2025.10.006_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2337\/diacare.27.8.1915","article-title":"The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes","volume":"27","author":"Harder","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2025.10.006_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.clnu.2025.10.006_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","article-title":"Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial","volume":"64","author":"Bouchi","year":"2017","journal-title":"Endocr J"},{"key":"10.1016\/j.clnu.2025.10.006_bib37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.clnu.2025.10.006_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12986-018-0295-6","article-title":"Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial","volume":"15","author":"Yin","year":"2018","journal-title":"Nutr Metab"},{"key":"10.1016\/j.clnu.2025.10.006_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial","volume":"10","author":"Feng","year":"2019","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.clnu.2025.10.006_bib40","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA Liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.clnu.2025.10.006_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154044","article-title":"Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents","volume":"103","author":"Gurjar","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2025.10.006_bib42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JCMA.0000000000000807","article-title":"Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy","volume":"86","author":"Fan","year":"2023","journal-title":"J Chin Med Assoc: JCMA"},{"key":"10.1016\/j.clnu.2025.10.006_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9926462","article-title":"Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts","volume":"2023","author":"Deng","year":"2023","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.clnu.2025.10.006_bib44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/hepr.12837","article-title":"Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol Res Off J Japan Soc Hepatol"},{"key":"10.1016\/j.clnu.2025.10.006_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105807","article-title":"Skeletal muscle atrophy: from mechanisms to treatments","volume":"172","author":"Yin","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clnu.2025.10.006_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.cellbio.20.012103.135836","article-title":"Regulation of muscle mass by myostatin","volume":"20","author":"Lee","year":"2004","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.clnu.2025.10.006_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.14283\/jfa.2017.33","article-title":"The vicious cycle of myostatin signaling in sarcopenic obesity: myostatin role in skeletal muscle growth, insulin signaling and implications for clinical trials","volume":"7","author":"Consitt","year":"2018","journal-title":"J Frailty Aging"},{"key":"10.1016\/j.clnu.2025.10.006_bib48","first-page":"56","article-title":"Myostatin (GDF-8) as a key factor linking muscle mass and bone structure","volume":"10","author":"Elkasrawy","year":"2010","journal-title":"J Musculoskelet Neuro Interact"},{"key":"10.1016\/j.clnu.2025.10.006_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semcdb.2017.11.010","article-title":"The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration","volume":"72","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.clnu.2025.10.006_bib50","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1038\/s41467-018-06583-6","article-title":"Myogenin promotes myocyte fusion to balance fibre number and size","volume":"9","author":"Ganassi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clnu.2025.10.006_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14336\/AD.2022.0622","article-title":"The role of sirtuins in sarcopenia and frailty","volume":"14","author":"Anwar","year":"2023","journal-title":"Aging Dis"},{"key":"10.1016\/j.clnu.2025.10.006_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111358","article-title":"Impact of physical activity on mitochondrial enzymes, muscle stem cell and anti-oxidant protein sestrins in sarcopenic mice","volume":"150","author":"Anwar","year":"2021","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.clnu.2025.10.006_bib53","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1152\/physrev.00038.2012","article-title":"Exercise, GLUT4, and skeletal muscle glucose uptake","volume":"93","author":"Richter","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clnu.2025.10.006_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044284","article-title":"Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia","volume":"7","author":"Green","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2025.10.006_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108951","article-title":"Biochemical and immunological changes in obesity","volume":"708","author":"Barakat","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.clnu.2025.10.006_bib56","first-page":"1503","article-title":"The diabetic muscle","volume":"71","author":"Kalra","year":"2021","journal-title":"J Pakistan Med Assoc"},{"key":"10.1016\/j.clnu.2025.10.006_bib57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.arr.2016.09.008","article-title":"Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis","volume":"35","author":"Kalinkovich","year":"2017","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.clnu.2025.10.006_bib58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1152\/japplphysiol.00627.2006","article-title":"Sarcopenic obesity and inflammation in the InCHIANTI study","volume":"102","author":"Schrager","year":"2007","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.clnu.2025.10.006_bib59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S0954422408138732","article-title":"Obesity and inflammation: the effects of weight loss","volume":"21","author":"Forsythe","year":"2008","journal-title":"Nutr Res Rev"},{"key":"10.1016\/j.clnu.2025.10.006_bib60","article-title":"Diagnostics of inflammaging in relation to sarcopenia","volume":"11","author":"Morawin","year":"2023","journal-title":"Front Pub Health"},{"key":"10.1016\/j.clnu.2025.10.006_bib61","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/jcsm.12417","article-title":"Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention","volume":"10","author":"Li","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2025.10.006_bib62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.maturitas.2016.11.006","article-title":"Inflammation and sarcopenia: a systematic review and meta-analysis","volume":"96","author":"Bano","year":"2017","journal-title":"Maturitas"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425002778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425002778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T23:02:26Z","timestamp":1768950146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561425002778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"alternative-id":["S0261561425002778"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2025.10.006","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}